跳转到内容

BT142

维基百科,自由的百科全书

BT142是首个在体内和体外均具有内源性IDH1英语IDH1突变及产生2-HG英语alpha-Hydroxyglutaric acid人类脑癌细胞系,最初分离自一名38岁的男性脑癌患者。BT142细胞有助于IDH1-突变型胶质瘤生物学研究,以及为靶向IDH1突变细肥的化合物的体内验证提供一个有效的模型[1]。BT142细胞成为神经球培养物后,体外分裂的进程就会变得非常缓慢,但是植入至小鼠纹状体后,细胞就会快速增殖,令到小鼠在大约12周后死亡[2]

参考资料

  1. ^ Luchman, HA; Stechishin, OD; Dang, NH; Blough, MD; Chesnelong, C; Kelly, JJ; Nguyen, SA; Chan, JA; Weljie, AM; Cairncross, JG; Weiss, S. An in vivo patient-derived model of endogenous IDH1-mutant glioma.. Neuro-oncology. 2012-02, 14 (2): 184–91 [2019-12-07]. PMID 22166263. doi:10.1093/neuonc/nor207. 
  2. ^ Kopinja, J; Sevilla, RS; Levitan, D; Dai, D; Vanko, A; Spooner, E; Ware, C; Forget, R; Hu, K; Kral, A; Spacciapoli, P; Kennan, R; Jayaraman, L; Pucci, V; Perera, S; Zhang, W; Fischer, C; Lam, MH. A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.. Scientific reports. 2017-10-23, 7 (1): 13853 [2019-12-07]. PMID 29062039. doi:10.1038/s41598-017-14065-w. 

外部链接